We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Bart Filius Joins Galapagos as CFO
News

Bart Filius Joins Galapagos as CFO

Bart Filius Joins Galapagos as CFO
News

Bart Filius Joins Galapagos as CFO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bart Filius Joins Galapagos as CFO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Galapagos NV has announced that Bart Filius, currently Vice President, CFO Sanofi Europe, will join Galapagos as Chief Financial Officer, effective 1 December 2014.

Bart Filius has over 13 years' experience at Sanofi. During the past three years as CFO Sanofi Europe, Bart was instrumental in transforming the Sanofi European organization to be well-positioned beyond the patent cliff.

Earlier at Sanofi, Bart was CFO and Country Manager of Sanofi in the Netherlands. Before that, he was Vice President for Mergers & Acquisitions, during which time Bart led and completed the divestiture of various franchises.

Prior to joining Sanofi, Bart was a strategy consultant at Arthur D. Little. Bart is a Dutch national and has an MBA degree from INSEAD and a bachelor's degree in business from Nyenrode University.

"We are pleased to welcome Bart Filius into our Executive team," said Onno van de Stolpe, CEO of Galapagos. "His vast experience in Big Pharma and his sharp strategic view will help us bring Galapagos to the next level, as we prepare to have our rheumatoid arthritis molecule GLPG0634 enter Phase 3 and progress more programs into patients next year."

"I am very excited to join Galapagos at this important point of its development", said Bart Filius. "As we move forward and the pipeline matures further, I look forward to bringing my experience in Finance and M&A to Galapagos."

Advertisement